Trials / Completed
CompletedNCT02388295
AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients
A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects With Multiple System Atrophy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD3241 | Drug: AZD3241 administered for 12 weeks orally as a tablet. |
| DRUG | Placebo | Placebo to match AZD3241 administered for 12 weeks orally as a tablet. |
Timeline
- Start date
- 2015-04-27
- Primary completion
- 2016-09-19
- Completion
- 2016-09-19
- First posted
- 2015-03-17
- Last updated
- 2017-09-25
- Results posted
- 2017-09-25
Locations
17 sites across 7 countries: United States, Austria, Finland, France, Italy, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT02388295. Inclusion in this directory is not an endorsement.